SCHEMBL29628247

SCHEMBL29628247

N=C(N)NCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GNPAT O15228 1/20 0.49
NPY4R P50391 11/20 0.47
NPY1R P25929 6/20 0.47
NPY2R P49146 4/20 0.47
NPY5R Q15761 4/20 0.47
NOD1 Q9Y239 3/20 0.42
FOLH1 Q04609 1/20 0.39
ENPEP Q07075 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30798042 1.00 GNPAT (0.49) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099629 0.99 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099502 0.99 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099491 0.99 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL31479945 0.99 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099484 0.99 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099714 0.99 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099449 0.96 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30099575 0.96 NPY4R (0.48) GNPATNPY4RNPY1RNPY2RNPY5R
SCHEMBL30798048 0.96 NPY4R (0.45) GNPATNPY4RNPY1RNPY2RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127939-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY PURDUE RESEARCH FOUNDATION 2025-04-24 US disclosed
EP-4541378-A2 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY Endocyte, Inc. (US) 2025-04-23 EP disclosed
US-12178892-B2 Compounds for positron emission tomography PURDUE RESEARCH FOUNDATION (US) 2024-12-31 US disclosed
US-20220125958-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY PURDUE RESEARCH FOUNDATION 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127939-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY VHL, PC, NPC1 GNPAT 49/4885NPY4R 4297/4885NPY1R 4092/4885
US-12178892-B2 Compounds for positron emission tomography FOLH1, FOLR2, FOLR1 GNPAT 1140/4885NPY4R 2363/4885NPY1R 1152/4885
US-20220125958-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY FOLH1, FOLR2, FOLR1 GNPAT 1140/4885NPY4R 2363/4885NPY1R 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.